Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

st at least 10% of their body weight compared to 9.7% for placebo (p<0.0001);

Lorcaserin 10 mg Once Daily

  • 40.2% of patients treated with 10 mg of lorcaserin dosed once daily lost at least 5% of their body weight (p<0.0001); and
  • 17.4% of patients treated with 10 mg of lorcaserin dosed once daily lost at least 10% of their body weight (p<0.0001).

Patients who took lorcaserin 10 mg twice daily achieved an average weight loss of 5.9% of their body weight, compared to 2.8% for placebo (p<0.0001). Similarly, patients who took lorcaserin 10 mg once daily achieved an average weight loss of 4.8% of their body weight (p<0.0001).

BLOSSOM Confirms BLOOM

In BLOSSOM, as in BLOOM, lorcaserin's excellent tolerability allowed patients to begin treatment at the full dose immediately, without a titration period, and achieve rapid weight loss. As in BLOOM, significant weight loss compared to placebo was shown at the first trial visit, two weeks following randomization.

The efficacy for the BLOOM and BLOSSOM trials after one year of treatment are summarized in the table below.

                               BLOOM                   BLOSSOM
                               -----                   -------


                       10 mg BID*  Placebo  10 mg BID*  10 mg QD*  Placebo
                       ----------  -------  ----------  ---------  -------
    >/=5% weight loss
     (Per protocol)       66.4%     32.1%     63.2%       53.1%     34.9%
    ---------------       ----      ----      ----        ----      ----
    >/=5% weight loss
     (ITT-LOCF)           47.5%     20.3%     47.2%       40.2%     25.0%
    ---------------       ----      ----      ----        ----      ----
    >/=10% weight loss
     (Per protocol) 
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, the ... Champions Tour, is rounding out its debut year of ... Scottsdale, AZ. This marks the ... Champions Tour that the brand has activated on-site with ... educate golf fans on the importance of joint health.  ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... 2012 Sorbent Therapeutics, Inc. a biopharmaceutical company developing ... from its Phase 2a clinical study of CLP1001.  In ... kidney disease, CLP1001 demonstrated improvement in heart failure symptoms ... the randomized, double-blind Phase 2a study were presented in ...
...  Eli Lilly and Company (NYSE: LLY ) ... 1 (GLP-1) analog being studied as a once-weekly treatment ... non-inferiority for mean 24-hour systolic blood pressure (SBP, or ... results came from a Phase II study that compared ...
Cached Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 2Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 4
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
(Date:10/30/2014)... Victory Healthcare, a privately owned ... quarter infection rates and patient satisfaction scores. The ... only two percent or less, and the medical ... percent. , “We are delighted with our strong ... scores,” said Robert Helms, chairman and CEO of ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... (HealthDay News) -- Many U.S. colleges have indoor ... tanning increases the risk for skin cancer, researchers ... particularly white women, so colleges should adopt tanning-free ... said. "Public health efforts are needed to ... the harms that indoor tanning poses to young ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... risk of hypertension, hardening of arteries , , FRIDAY, May 15 ... harbor could be a cause of high blood pressure, animal ... likely to develop not only high blood pressure but also ... report in the May 15 issue of PLoS Pathogens ...
... Boston Scientific Corporation (NYSE: BSX ) ... news announcements at the annual EuroPCR Scientific Program, which ... are pleased to be announcing additional analyses from the ... outcomes, as well as insights on the design and ...
... ATLANTA, May 15 Paul Capital Healthcare today announced ... a panel on non-traditional forms of financing at the ... with how to evaluate non-dilutive financing options that can ... development, the panel, "Non-dilutive and Other Non-traditional Forms of ...
... establish Group B Strep colonization of pregnant women and ... newbornsGBS PNA FISH shown to detect up to 42% ... and VEDBAEK, Denmark, May 15 AdvanDx today announced ... for detection of Streptococcus agalactiae , aka Group ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and ... ... (PRWEB) May 15, 2009 -- Kinovate Life Sciences, Inc, the ... announcing the successful development of its next generation high loading ...
Cached Medicine News:Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 2Health News:Boston Scientific Announces Schedule for EuroPCR 2009 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 4Health News:Boston Scientific Announces Schedule for EuroPCR 2009 5Health News:Boston Scientific Announces Schedule for EuroPCR 2009 6Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 3Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase&#8482; HL High Loading Solid Support for Oligonucleotide Synthesis 2Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase&#8482; HL High Loading Solid Support for Oligonucleotide Synthesis 3Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase&#8482; HL High Loading Solid Support for Oligonucleotide Synthesis 4
... Excellent performance, small footprint, simple intuitive programming ... Primus 25 the ideal personal cycler in ... flexiblock design and the self-adjusting heated lid ... 13x 0.5ml vessels or a microplate of ...
... 96 temperature cyclers, the gradient block can be ... up to 14 or 22 across the 40- ... of up to 2C between adjacent wells in ... to 12 different annealing temperatures in a single ...
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... analysis software, Beacon Designer oligo software, ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
Medicine Products: